BACKGROUND: Currently, direct-acting antivirals (DAAs) are the first-line treatment for patients with chronic hepatitis C (CHC) and mixed cryoglobulinemia syndrome (MCS). However, the prognosis is variable as the achievement of sustained virological response (SVR) is not always associated with clinical remission of MCS. CASE REPORT: We describe a case of CHC-MCS treated with the new DAA combination Glecaprevir/Pibrentasvir (GLE/PIB). The reported patient achieved SVR accompanying by complete clinical remission of MCS. CONCLUSION: Patients with CHC-MCS vasculitis would benefit from antiviral treatment with GLE/PIB. HIPPOKRATIA 2019, 23(1): 30-32. Copyright 2019, Hippokratio General Hospital of Thessaloniki.
BACKGROUND: Currently, direct-acting antivirals (DAAs) are the first-line treatment for patients with chronic hepatitis C (CHC) and mixed cryoglobulinemia syndrome (MCS). However, the prognosis is variable as the achievement of sustained virological response (SVR) is not always associated with clinical remission of MCS. CASE REPORT: We describe a case of CHC-MCS treated with the new DAA combination Glecaprevir/Pibrentasvir (GLE/PIB). The reported patient achieved SVR accompanying by complete clinical remission of MCS. CONCLUSION:Patients with CHC-MCS vasculitis would benefit from antiviral treatment with GLE/PIB. HIPPOKRATIA 2019, 23(1): 30-32. Copyright 2019, Hippokratio General Hospital of Thessaloniki.
Authors: Edward Gane; Eric Lawitz; David Pugatch; Georgios Papatheodoridis; Norbert Bräu; Ashley Brown; Stanislas Pol; Vincent Leroy; Marcello Persico; Christophe Moreno; Massimo Colombo; Eric M Yoshida; David R Nelson; Christine Collins; Yang Lei; Matthew Kosloski; Federico J Mensa Journal: N Engl J Med Date: 2017-10-12 Impact factor: 91.245